Abstracts tagged "Autoantibody(ies)"

Abstract Number: 2350 • ACR Convergence 2023
Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303; TACI vTD-Fc)
Tiffany Blair, Elizabeth Repash, Armand Bankhead, Amanda Enstrom, Lawrence Evans, Susan Debrot, Allison Chunyk, Sherri Mudri, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are cytokines that signal through transmembrane activator and CAML interactor (TACI), B cell maturation…
Abstract Number: 0099 • ACR Convergence 2023
Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases
Doruk Erkan¹, JoAnn Vega¹, Tyler O'Malley² and Andrew Concoff³, ¹Hospital for Special Surgery, New York, NY, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Based on animal models, complement activation is part of Antiphospholipid Syndrome (APS) pathogenesis. However, studies investigating complement activation in antiphospholipid antibody (aPL)-positive patients are…
Abstract Number: 0581 • ACR Convergence 2023
Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases
Daphne Bijlsma, Ewa Lukasik, Michael Hausmann, Gerber Gomez, Christine Ginocchio and Emmanuel Moreau, Quotient Suisse SA, Eysins, Switzerland
Background/Purpose: Detection of autoantibodies is key for the identification and prognosis of patients with connective tissue diseases (CTD); however, some current testing methods are manual,…
Abstract Number: 0917 • ACR Convergence 2023
Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus
Victor Gothefors-Holm¹, Sarah Reid¹, Ahmed Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jonsen⁴, Solbritt Rantapää-Dahlqvist⁵, Anders Bengtsson⁴, Anna Rudin⁶, Oyvind Molberg³, Christopher Sjöwall², Johanna Sandling¹, Lars Rönnblom¹ and Dag Leonard¹, ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease partly characterized by production of autoantibodies, causing inflammation and tissue damage. In this study…
Abstract Number: 1448 • ACR Convergence 2023
Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients
Natalia Guajardo-Jauregui¹, Iris Colunga², José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Jesus Alberto Cardenas-De la Garza³ and Rosa Arvizu-Rivera⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that involves the deposition of immunocomplexes on vital organs, including the heart. Cardiovascular disease is…
Abstract Number: 1809 • ACR Convergence 2023
Clinical Outcome and Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection Among Patients with Systemic Autoimmune Diseases
Zhu Chen¹, nan xiang¹, Qian Wang¹, Yuwei Li¹, Huizhi Jin¹, Guosheng Wang¹, Xiaomei Li², Tengchuan Jin¹ and Wei Bao¹, ¹University of Science and Technology of China, Hefei, China, ²University of Science and Technology of China, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China
Background/Purpose: The surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron infections has affected most Chinese residents at the end of 2022, including…
Abstract Number: 2405 • ACR Convergence 2023
Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis
Despoina Michailidou¹, Peter Grayson², Payton Hermanson¹, Jorge Armando Gonzalez-Chapa¹, David Cuthbertson³, Nader A. Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Larry Moreland⁸, Christian Pagnoux⁹, Philip Seo¹⁰, Antoine G Sreih¹¹, Kenneth Warrington¹², Paul Monach¹³, Peter Merkel⁷ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸University of Colorado, Denver, CO, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Bristol Myers Squibb, Princeton Pike, NJ, ¹²Mayo Clinic, Rochester, MN, ¹³VA Boston Healthcare System, Boston, MA
Background/Purpose: We recently found extracellular mitochondrial-derived N-formyl methionine in patients with giant cell arteritis (GCA. Extracellular mitochondria can be extruded by several mechanisms, including platelet…
Abstract Number: 0101 • ACR Convergence 2023
Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome
Elizabeth Sloan¹, Katarina Kmetova², NaveenKumar K. Somanathapura², Lyndsay Kluge², Emily Chong², Claire Hoy², Srilakshmi Yalavarthi², Jacqueline Madison², Cyrus Sarosh², Lynnette Walters³, Jeanine Baisch⁴, Jessica Turnier², Virginia Pascual⁴, Tracey Wright¹, Jason Knight², Ayesha Zia¹ and Yu Zuo², ¹UT Southwestern, Dallas, TX, ²University of Michigan, Ann Arbor, MI, ³Scottish Rite Hospital for Children, Dallas, TX, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: While classification criteria for pediatric APS are not yet available, recent research suggests pediatric APS patients are unique, and many present with extra-criteria manifestations…
Abstract Number: 0602 • ACR Convergence 2023
Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus
Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…
Abstract Number: 0927 • ACR Convergence 2023
A Complex Interplay Among Gut Lachnoclostidium, HLA Haplotype DRB1*07:01, and the TNF Superfamily in Anti-Ro+ Women with a Spectrum of Preclinical and Clinical Autoimmunity Whose Children Have Neonatal Lupus
Robert Clancy¹, Caroline Izmirly¹, Miranda Marion², Nicola Fraser¹, Joel Guthridge³, Timothy Howard², Peter Izmirly⁴, Mala Masson⁵, Jill Buyon¹, Judith James³ and Carl Langefeld⁶, ¹NYU Grossman School of Medicine, New York, NY, ²Wake Forest University, Winston-Salem, NC, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴New York University School of Medicine, New York, NY, ⁵New York University, New York, NY, ⁶Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Mothers of children with neonatal lupus (NL) are often clinically asymptomatic or have insufficient criteria for a formal rheumatologic diagnosis, despite having high titers…
Abstract Number: 1458 • ACR Convergence 2023
Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Kittikorn Wangriatisak¹, Francesca Faustini², Charlotte de Vries³, Ravi Kumar Sharma⁴, Caroline Grönwall⁵, Prapaporn Pisitkun⁶, Patchanee Chootong⁷, Vivianne Malmström⁵ and Iva Gunnarsson⁸, ¹Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, ⁷Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, ⁸Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 2434 • ACR Convergence 2023
Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Arnoud de Ru, Peter van Veelen, Thomas Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gut-residing bacteria, such as E.coli, can acetylate their proteome under conditions of amine starvation. It is postulated that the (gut) microbiome is involved in…
Abstract Number: 0105 • ACR Convergence 2023
Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
Yin Long¹, Jiuliang zhao², Mengtao Li² and Xiaofeng Zeng², ¹Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
Abstract Number: 0603 • ACR Convergence 2023
Antiphospholipid Antibodies as Potential Predictors of Disease Severity and Poor Prognosis in Systemic Lupus Erythematosus Associated Thrombocytopeinia
Mehret Birru Talabi¹, Bonnie Bermas², Irene Blanco³, Ashira Blazer⁴, Megan Clowse⁵, Cuoghi Edens⁶, Leslie Pierce⁷, Catherine Wright¹ and Rosalind Ramsey-Goldman³, ¹University of Pittsburgh, Pittsburgh, PA, ²UT Southwestern, Dallas, TX, ³Northwestern University, Chicago, IL, ⁴Hospital for Special Surgery, New York, NY, ⁵Duke University, Chapel Hill, NC, ⁶University of Chicago, Chicago, IL, ⁷University of Pittsburgh, Raleigh, NC
Background/Purpose: Thrombocytopenia (TP) is a common hematologic abnormality in systemic lupus erythematosus (SLE). Severe thrombocytopenia is correlated with disease activity and a worse prognosis of…

« Previous Page
1
…
8
9
10
11
12
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].